
AllRock Bio Raises $50 Million Series A to Advance Pulmonary Hypertension Treatment
AllRock Bio Inc., a clinical-stage biotechnology company focused on advancing therapies for cardiopulmonary and fibrotic diseases, announced a $50 million Series A round co-led by Versant Ventures and Westlake BioPartners. Proceeds will advance AllRock's lead molecule, ROC-101, which the company…


















